Adma Biologics (ADMA) Gross Profit (2011 - 2026)
Adma Biologics' (ADMA) quarterly Gross Profit came in at $88.8 million in Q4 2025, up 40.24% YoY from $63.3 million in Q4 2024, and up 17.44% on a QoQ basis from $75.6 million in Q3 2025.
Adma Biologics (ADMA) Gross Profit (2011 - 2026) Analysis & Trends
Adma Biologics (ADMA) has 13 years of Gross Profit data on file, last reported at $88.8 million in Q4 2025.
- Quarterly Gross Profit rose 40.24% year-over-year to $88.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $292.8 million (up 33.35% YoY) and the FY2025 annual result came in at $292.8 million, up 33.35% from the prior year.
- Gross Profit climbed to $88.8 million in Q4 2025, from $75.6 million in the prior quarter.
- In the past five years, Gross Profit ranged from a high of $88.8 million in Q4 2025 to a low of -$1.7 million in Q1 2021.
- A 5-year average of $31.9 million and a median of $20.7 million in 2023 frame the typical range for Gross Profit.
- Annual changes were most pronounced in 2021 — Gross Profit tumbled 114.5% — and 2022, when it soared 2406.02%.
- Tracing ADMA's Gross Profit over 5 years: stood at $3.5 million in 2021, then jumped by 303.76% to $14.2 million in 2022, then surged by 119.27% to $31.1 million in 2023, then surged by 103.73% to $63.3 million in 2024, then soared by 40.24% to $88.8 million in 2025.
- The last three Gross Profit figures came in at $88.8 million (Q4 2025), $75.6 million (Q3 2025), and $67.2 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Adma Biologics | 2.13 Bn | 2.00 Bn | 86.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 86.28 Mn |
| Jun 30, 2026 | 86.28 Mn |
| Dec 31, 2025 | 88.82 Mn |
| Dec 31, 2025 | 88.82 Mn |
| Sep 30, 2025 | 75.63 Mn |
| Sep 30, 2025 | 75.63 Mn |
| Jun 30, 2025 | 67.23 Mn |
| Jun 30, 2025 | 67.23 Mn |
| Mar 31, 2025 | 61.10 Mn |
| Mar 31, 2025 | 61.10 Mn |
| Dec 31, 2024 | 63.33 Mn |
| Dec 31, 2024 | 63.33 Mn |
| Sep 30, 2024 | 59.66 Mn |
| Sep 30, 2024 | 59.66 Mn |
| Jun 30, 2024 | 57.45 Mn |
| Jun 30, 2024 | 57.45 Mn |
| Mar 31, 2024 | 39.11 Mn |
| Mar 31, 2024 | 39.11 Mn |
| Dec 31, 2023 | 31.09 Mn |
| Dec 31, 2023 | 31.09 Mn |